Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmala Biotech Holdings Inc MDXXF


Primary Symbol: C.MDMA

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines... see more

Recent & Breaking News (CSE:MDMA)

PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License

GlobeNewswire 7 days ago

Canadian psychedelic stock to supply MDMA to Yale

Trevor Abes  November 7, 2024

PharmAla to supply LaNeo MDMA for Clinical Trial at Yale

GlobeNewswire November 7, 2024

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA

GlobeNewswire October 21, 2024

PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo(TM) MDMA

GlobeNewswire October 8, 2024

PharmAla to supply Harvard Medical School trial with MDMA

Jonathon Brown October 2, 2024

PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA

GlobeNewswire October 2, 2024

PharmAla to supply Johns Hopkins Medicine for Clinical Trial

GlobeNewswire September 11, 2024

PharmAla Launches MDMA Clinical Trial Tool for Researchers

GlobeNewswire August 22, 2024

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

GlobeNewswire August 9, 2024

PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement

GlobeNewswire July 30, 2024

PharmAla Biotech launches educational portal for MDMA

Jocelyn Aspa May 3, 2024

PharmAla Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy

GlobeNewswire May 3, 2024

PharmAla Closes Private Placement and Concurrent Debt Settlement

GlobeNewswire April 19, 2024

PharmAla Announces Private Placement and Concurrent Debt Settlement

GlobeNewswire April 10, 2024

Cortexa Commences Manufacturing GMP LaNeo(TM) MDMA in Australia

GlobeNewswire April 5, 2024

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

GlobeNewswire March 27, 2024

PharmAla Biotech Signs Sale Agreement with Numinus

GlobeNewswire March 26, 2024

Canadian Investment Regulatory Organization Trade Resumption - MDMA

Canada NewsWire March 20, 2024

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

GlobeNewswire March 20, 2024